Tumor Ablation Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Tumor Ablation Market is segmented By Technology (Radiofrequency (rf) Ablation, Microwave Ablation, Cryoablation, Other Technologies), By Application (Liver cancer, Lung cancer, Kidney cancer, Bone Metastasis, Others), By Treatment Mode (Surgical Ablation, Laparoscopic Ablation, Percutaneous Ablation), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Tumor Ablation Market Size

The Global Tumor Ablation Market reached US$ 797.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,079.2 million by 2031. The global tumor ablation market is expected to exhibit a CAGR of 13.1% during the forecast period (2024-2031). 

There are several types of tumor ablation procedures, including radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, high-intensity focused ultrasound (HIFU), and laser ablation. Each procedure uses a different energy source to heat or freeze the cancerous tissue, causing it to be destroyed.

Furthermore, the global market for tumor ablation is driven by several factors, including the increasing prevalence of cancer, advancements in ablation technologies, growing demand for minimally invasive procedures, and favorable reimbursement policies.

Tumor Ablation Market Summary

To know more insights Download Sample

Tumor Ablation Market Dynamics

The Increasing Use of Novel Technologies for Treating Difficult-To-Treat Cancers is Driving the Global Tumor Ablation Market Growth

In 2022, Joseph Whitlark, M.D. of Crozer Health performed a minimally invasive procedure for a patient with metastatic cancer using a novel technology called Aliya Pulsed Electric Field (PEF). Crozer Health is one of seven healthcare centers in the U.S. to offer this technology, which is designed to ablate target cells and activate the patient's immune system against the tumor.

Aliya PEF delivers brief, high-amplitude, non-thermal pulsed energy to target tissue, killing the cells without damaging surrounding tissue. It is minimally invasive, only requiring a single needle, and causes little pain or discomfort for the patient. 

The technology's waveform and electrode may stimulate an immune response and disrupt the immunosuppressive tumor microenvironment by releasing tumor antigens. This advancement is significant and could revolutionize cancer treatment, even in its early stages of use.

This novel approach to tumor ablation could be a game-changer in cancer treatment, and as a result, it is likely to drive the market by increasing demand for this new technology. Additionally, the success of this technology could encourage further research and development of other novel approaches to tumor ablation, leading to further growth in the market.

The High Cost of Tumor Ablation Procedures is Hampering the Growth of the Global Tumor Ablation Market

The cost of current cryoablation technologies is one factor that can limit access to this type of treatment. A single cryoablation treatment can cost over $10,000, making it unaffordable for many patients. Additionally, the devices used for cryoablation require argon gas to form the tissue-killing ice crystals, which may not be readily available in lower-income countries. 

This lack of availability of argon gas can limit the use of cryoablation in these regions, further exacerbating the health disparities that already exist. However, ongoing research and development of cryoablation technologies may lead to improvements in efficiency and cost-effectiveness, making it more accessible to a wider range of patients in the future.

Tumor Ablation Market Segment Analysis

The global tumor ablation market is segmented based on technology, application, treatment mode, and region.

The Microwave Ablation Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.

The microwave ablation segment accounted for the highest market stake accounting for approximately 2/3 of the tumor ablation market in 2022. Microwave ablation (MWA) is a type of tumor ablation therapy that uses high-frequency microwave energy to heat and destroy cancer cells. The advantages of microwave ablation include speed, precision, effectiveness, minimal invasiveness, and safety.

Furthermore, the increasing prevalence of cancer, the rising geriatric population, advancements in technology, and the increasing availability of MWA devices in hospitals and clinics are the factors expected to drive the market over the forecast period.

For instance, according to the American Cancer Society Journal, it is estimated that in 2022, there will be 1,918,030 new cases of cancer and 609,360 deaths in the United States. Lung cancer is projected to be the leading cause of cancer deaths, with approximately 350 deaths per day. Female breast cancer incidence has shown a slow increase of 0.5% annually during the period of 2014 through 2018, while prostate cancer incidence has remained stable despite an annual increase of 4% to 6% for advanced disease since 2011.

Consequently, the number of cancer cases continues to rise, there is an increasing demand for effective and minimally invasive treatments like MWA. This is because MWA is an effective treatment option for various types of cancers, including liver, lung, breast, and kidney cancer, among others. Thus, owing to the above factors, the microwave ablation segment is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Global Tumor Ablation Market Geographical Share

North America Holds a Dominant Position in the Global Tumor Ablation Market.

North America is estimated to hold around 1/3 of the total market share throughout the forecast period, owing to the increasing prevalence of cancer, the launch, and approval of new products, the rising geriatric population, and technological advancement in ablation devices are the factors expected to boost regional growth over the forecast period.

For instance, in March 2022, Quantum Surgical, a medical device company specializing in ablation devices, obtained approval from the United States Food and Drug Administration (US FDA) for its new Epione system. The Epione system is a category of interventional oncology robotics that is designed for minimally invasive liver cancer treatment. The system employs computer-guided needles to plan and execute outpatient ablation surgery, enabling precise targeting and destruction of tumors through the skin. 

Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Tumor Ablation Market Companies

The major global players in the market include Medtronic, PLC., AngioDynamics Inc., Boston Scientific Corporation, Healthtronics, BVM Medical Limited, COMSOL, Galil Medical, Inc., INTIO Inc., Misonix, Inc., NeuWave Medical, Inc., and SonaCare Medical among others.

Russia Ukraine Conflict Analysis:

The Russia-Ukraine conflict has an impact on the tumor ablation market because it could disrupt the supply chain and manufacturing of medical devices and technologies needed for the treatments. This could lead to shortages or increased costs for patients. Additionally, if hospitals and healthcare facilities are damaged during the conflict, it could limit the availability of treatments for cancer patients. Thus, from the factors mentioned above, it can be inferred that the war has had a moderate impact on the tumor ablation market during the forecast period.

Key Developments

• Imagin Medical, a company focused on urologic oncology based in Canada, recently purchased the enCAGE Coil Precision Ablation System for Prostate Cancer from TROD Medical NV, a medical device company based in Belgium. The acquisition, which was completed in August 2022, was valued at $2.5 million. With this acquisition, Imagin Medical aims to strengthen its position in the field of urologic oncology and expand its portfolio in the area of prostate cancer.
• In March 2023, AngioDynamics announced that it formed a new partnership with Minimax Medical for the international distribution of its product portfolio. The new distribution arrangement with Minimax Medical becomes effective on November 15, 2022. The partnership will include the distribution of Minimax Medical’s leading Radiofrequency Ablation System for tumors/nodules on an international level.
• In August 2022, Bioventus Inc., a global leader in innovations for active healing, announced that the US Food and Drug Administration (FDA) granted 510(k) clearance for the company’s neXus SonaStar Elite handpiece. The SonaStar Elite (SSE) handpiece is powered by the neXus Ultrasonic Surgical Aspirator System, a next-generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm resulting in more versatility and control. The neXus system combines all the features of soft and hard (including bone) tissue removal into a single fully integrated platform capable of operating at multiple frequencies, including the newly approved 36 kHz SonaStar Elite Handpiece.

Why Purchase the Report?

• To visualize the global tumor ablation market segmentation based on the technology, application, treatment mode, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of tumor ablation market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global tumor ablation market report would provide approximately 61 tables, 60 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies